{"entity":{"id":"nct07417189","kind":"trial","name":"A Phase I/II Study of ABSK141 in Patients With Advanced Solid Tumors ( ABSK141-101 )","aka":[],"tldr":"A phase 1/2 trial of ABSK141-400mg in advanced solid tumours, run by Abbisko Therapeutics Co, Ltd, now recruiting.","summary":"A Phase I/II Study of ABSK141 in Patients With Advanced Solid Tumors ( ABSK141-101 ) is a phase 1/2 interventional study registered as NCT07417189 by Abbisko Therapeutics Co, Ltd, with 401 participants planned, started 2026-03-02 and due to reach its primary completion in 2028-12-30. Interventions recorded: ABSK141-400mg, ABSK141-Recommended Dose for Expansion (RDE), ABSK141-800mg, ABSK141-1200mg and ABSK141-Recommended Phase 2 dose (RP2D).","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07417189","url":"https://clinicaltrials.gov/study/NCT07417189"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["abbisko"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07417189","phase":"1/2","setting":"A Phase I/II, Open-Label Study of ABSK141 to Assess Safety, Tolerability, Efficacy and Pharmacokinetics in Patients With KRAS G12D Mutant Advanced Solid Tumors","sponsor":"Abbisko Therapeutics Co, Ltd","enrolled":401,"outcomes":[]},"route":"/trials/nct07417189/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"abbisko","kind":"company","name":"Abbisko Therapeutics","route":"/companies/abbisko/"}]}}